DE69923996D1 - Methode für die herstellung von gereinigtem invasinprotein und seine anwendung - Google Patents

Methode für die herstellung von gereinigtem invasinprotein und seine anwendung

Info

Publication number
DE69923996D1
DE69923996D1 DE69923996T DE69923996T DE69923996D1 DE 69923996 D1 DE69923996 D1 DE 69923996D1 DE 69923996 T DE69923996 T DE 69923996T DE 69923996 T DE69923996 T DE 69923996T DE 69923996 D1 DE69923996 D1 DE 69923996D1
Authority
DE
Germany
Prior art keywords
production
cleaned
application
invasin protein
highly purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69923996T
Other languages
English (en)
Inventor
D Picking
L Picking
V Oaks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Center for Research Inc (KUCR)
Walter Reed Army Institute of Research
Original Assignee
University of Kansas Center for Research Inc (KUCR)
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Center for Research Inc (KUCR), Walter Reed Army Institute of Research filed Critical University of Kansas Center for Research Inc (KUCR)
Application granted granted Critical
Publication of DE69923996D1 publication Critical patent/DE69923996D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69923996T 1998-10-21 1999-10-21 Methode für die herstellung von gereinigtem invasinprotein und seine anwendung Expired - Lifetime DE69923996D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10508598P 1998-10-21 1998-10-21
US13675499P 1999-06-01 1999-06-01
PCT/US1999/024931 WO2000023462A1 (en) 1998-10-21 1999-10-21 Method for the production of purified invasin protein and use thereof

Publications (1)

Publication Number Publication Date
DE69923996D1 true DE69923996D1 (de) 2005-04-07

Family

ID=26802247

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923996T Expired - Lifetime DE69923996D1 (de) 1998-10-21 1999-10-21 Methode für die herstellung von gereinigtem invasinprotein und seine anwendung

Country Status (7)

Country Link
US (1) US20070202124A1 (de)
EP (1) EP1131338B1 (de)
AT (1) ATE290012T1 (de)
AU (1) AU1227700A (de)
CA (1) CA2347937A1 (de)
DE (1) DE69923996D1 (de)
WO (1) WO2000023462A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025058D0 (en) * 2000-10-12 2000-11-29 Smithkline Beecham Biolog Composition
CA2548202C (en) * 2003-11-25 2013-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
US7833740B2 (en) 2005-08-07 2010-11-16 Tgc Biomics Gmbh Test system for detecting salmonella
DE102005037796A1 (de) * 2005-08-07 2007-02-08 Tgc Biomics Gmbh Testsystem zum Nachweis von Salmonellen
CN101711165B (zh) * 2007-03-27 2016-02-24 以沃尔特里德军事研究所的名义,由美国陆军部部长为代表的美国政府 人造侵袭素复合物
DE102010018085A1 (de) * 2010-04-23 2011-10-27 Bioserv Analytik Und Medizinprodukte Gmbh Verfahren zur Erkennung einer Salmonelleninfektion
US9492523B2 (en) * 2011-12-09 2016-11-15 The Board Of Regents For Oklahoma State University Broadly protective Shigella vaccine based on type III secretion apparatus proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
FR2567541B1 (fr) * 1984-07-13 1987-02-06 Pasteur Institut Sonde d'adn et procede pour la detection de " shigelles " et des souches entero-invasives de escherichia coli
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5196338A (en) * 1986-12-31 1993-03-23 Praxis Biologics, Inc. Recombinant vectors for Haemophilus influenzae peptides and proteins
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5041372A (en) * 1988-11-02 1991-08-20 The United States Of America As Represented By The Department Of Health And Human Services Probe to identify enteroinvasive E. coli and Shigella species
DE3843627A1 (de) * 1988-12-21 1990-07-05 Inst Genbiologische Forschung Kartoffelknollenspezifische transkriptionale regulation
US5594115A (en) * 1990-04-09 1997-01-14 Pharmacia & Upjohn Company Process of purifying recombinant proteins and compounds useful in such process
US5726293A (en) * 1992-10-02 1998-03-10 The General Hospital Corporation Affinity purification methods involving imidazole elution
US5552294A (en) * 1992-10-20 1996-09-03 Children's Medical Center Corporation Rapid detection of virulence-associated factors
US5834247A (en) * 1992-12-09 1998-11-10 New England Biolabs, Inc. Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6861247B1 (en) * 1995-11-14 2005-03-01 The General Hospital Corporation Salmonella secreted proteins and uses thereof
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6303302B1 (en) * 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression

Also Published As

Publication number Publication date
CA2347937A1 (en) 2000-04-27
US20070202124A1 (en) 2007-08-30
EP1131338A1 (de) 2001-09-12
ATE290012T1 (de) 2005-03-15
WO2000023462A1 (en) 2000-04-27
EP1131338A4 (de) 2002-08-28
EP1131338B1 (de) 2005-03-02
AU1227700A (en) 2000-05-08

Similar Documents

Publication Publication Date Title
HUP0301815A2 (hu) Fertżzż és egyéb betegségek kezelésére használható mono- és diszacharid alapú gyógyszerkészítmény és profilaktikus és terápiás kezelés
HUP0303996A2 (hu) Vakcinakészítmények
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
NO993847D0 (no) Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
DE59710177D1 (de) Omega-3-fettsäurehaltige zubereitung aus mikroorganismen als prophylaktikum bzw. therapeutikum gegen kokzidiose bei tieren
DK0764209T3 (da) Albuminekspression i gær
HUP0302965A2 (hu) Vakcina
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
ATE108067T1 (de) Impfstoff und verfahren zur herstellung.
LU93259I2 (fr) LETIFEND (Protein Q)
NO965621L (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
EP0245433A4 (de) Wichtigstes protein von neisseria gonorrhöe mit eisenregelung und dessen verwendung.
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69923996D1 (de) Methode für die herstellung von gereinigtem invasinprotein und seine anwendung
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини
FI913100A0 (fi) Farmaceutiska preparat.
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
DE3685917D1 (de) Peptid-zusammensetzung fuer die herstellung von malaria-impfstoff, sowie fuer die vorbereitung von diagnostischen einzelteilen fuer den nachweis von malaria-aehnlichen krankheiten.
ATE349531T1 (de) Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
DE69200412D1 (de) 3-substituierte 1,2,3,4-oxatriazol-5-iminderivate, verfahren zur herstellung sowie diese enthaltende arzneimittel.
IT9020968A0 (it) Metodi e composizioni farmaceutiche per il trattamento di malattie oftalmiche
DE69116606D1 (de) Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
ATE297408T1 (de) Verfahren zur isolierung und aufreinigung von gräserpollenallergenen

Legal Events

Date Code Title Description
8332 No legal effect for de